In-depth investigation on physicochemical and thermal properties of magnesium (II) gluconate using spectroscopic and thermoanalytical techniques

By Mahendra Kumar Trivedi1, Neena Dixit2, Parthasarathi Panda3, Kalyan Kumar Sethi3, Snehasis Jana3

1. Trivedi Global Inc. 2. National Institute of Technology 3. Trivedi Science Research Laboratory Pvt. Ltd.

Published on


Magnesium gluconate is a classical organometallic pharmaceutical compound used for the prevention and treatment of hypomagnesemia as a source of magnesium ion. The present research described the in-depth study on solid state properties viz. physicochemical and thermal properties of magnesium gluconate using sophisticated analytical techniques like Powder X-ray diffraction (PXRD), particle size analysis (PSA), Fourier transform infrared (FT-IR) spectrometry, ultraviolet–visible (UV–Vis) spectroscopy, thermogravimetric analysis (TGA)/differential thermogravimetric analysis (DTG), and differential scanning calorimetry (DSC). Magnesium gluconate was found to be crystalline in nature along with the crystallite size ranging from 14.10 to 47.35 nm. The particle size distribution was at d(0.1)=6.552 µm, d(0.5)=38.299 µm, d(0.9)=173.712 µm and D(4,3)=67.122 µm along with the specific surface area of 0.372 m2/g. The wavelength for the maximum absorbance was at 198.0 nm. Magnesium gluconate exhibited 88.51% weight loss with three stages of thermal degradation process up to 895.18 °C from room temperature. The TGA/DTG thermograms of the analyte indicated that magnesium gluconate was thermally stable up to around 165 °C. Consequently, the melting temperature of magnesium gluconate was found to be 169.90 °C along with the enthalpy of fusion of 308.7 J/g. Thus, the authors conclude that the achieved results from this study are very useful in pharmaceutical and nutraceutical industries for the identification, characterization and qualitative analysis of magnesium gluconate for preformulation studies and also for developing magnesium gluconate based novel formulation.


[1] S. Ramachandran, P. Fontanille, A. Pandey, et al., Gluconic acid: properties, applications and microbial production, Food Technol. Biotechnol. 44 (2006) 185–195.

[2] M.K. Choi, C.M. Weaver, Daily intake of magnesium and its relation to urinary excretion in Korean healthy adults consuming self-selected diets, Biol. Trace Elem. Res. 176 (2017) 105–113.

[3] R. Ponka, E. Fokou, E. Beaucher, et al., Nutrient content of some Cameroonian traditional dishes and their potential contribution to dietary reference intakes, Food Sci. Nutr. 4 (2016) 696–705.

[4] N.J. Birch, Magnesium in biology and medicine: an overview in Metal ions in biological systems, H. Sigel, A. Sigel (Eds.), , Compendium on Magnesium and its Role in Biology, Nutrition and Physiology Vol. 26, Marcel Dekker Inc, New York, 1990: 105–115

[5] J.H. William, J. Danziger, Magnesium deficiency and proton-pump inhibitor use: a clinical review, J. Clin. Pharmacol. 56 (2016) 660–668.

[6] R. Swaminathan, Magnesium metabolism and its disorders, Clin. Biochem. Rev. 24 (2003) 47–66.

[7] J.G. Gums, Magnesium in cardiovascular and other disorders, Am. J. Health Syst. Pharm. 61 (2004) 1569–1576.

[8] C.H. Sales, Lde F. Pedrosa, Magnesium and diabetes mellitus: their relation, Clin. Nutr. 25 (2006) 554–562.

[9] M.P. Guerrera, S.L. Volpe, J.J. Mao, Therapeutic uses of magnesium, Am. Fam. Physician 80 (2009) 157–162.

[10] B.I. Nageris, D. Ulanovski, J. Attias, Magnesium treatment for sudden hearing loss, Ann. Otol. Rhinol. Laryngol. 113 (2004) 672–675.

[11] U. Gröber, J. Schmidt, K. Kisters, Magnesium in prevention and therapy, Nutrients 7 (2015) 8199–8226.

[12] T.E. Fleming, H.C. Mansmann Jr., Methods and compositions for the prevention and treatment of diabetes mellitus, United States Patent 5871769, 1999.

[13] T.E. Fleming, H.C. Mansmann Jr., Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections, United States Patent 5939394, 1999.

[14] W.B. Weglicki, Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution, United States Patent 6100297, 2000.

[15] R.W. Martin, J.N. Martin Jr, J.A. Pryor, et al., Comparison of oral ritodrine and magnesium gluconate for ambulatory tocolysis, Am. J. Obstet. Gynecol. 158 (1988) 1440–1445.

[16] R.J. Turner, K.W. Dasilva, C. O'Connor, et al., Magnesium gluconate offers no more protection than magnesium sulphate following diffuse traumatic brain injury in rats, J. Am. Coll. Nutr. 23 (2004) 541S–544S.

[17] K.H. Lee, S.H. Chung, J.H. Song, et al., Cosmetic compositions for skin-tightening and method of skin-tightening using the same, United States Patent 8580741 B2, 2013.

[18] C. Coudray, M. Rambeau, C. Feillet-Coudray, et al., Study of magnesium bioavail-ability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach, Magnes. Res. 18 (2005) 215–223.

[19] H.G. Brittain, Polymorphism in Pharmaceutical Solids in Drugs and Pharmaceutical Sciences, 2nd ed. Vol. 192, Informa Healthcare USA, Inc., New York, 2009.

[20] K.R. Gupta, S.S. Askarkar, R.R. Joshi, et al., Solid state properties: preparation and characterization, Der Pharm. Sin. 6 (2015) 45–64.

[21] R.A. Storey, I. Ymen, Solid State Characterization of Pharmaceuticals, Wiley-Blackwell, UK, 2011.

[22] P. Guerrieri, A.C.F. Rumondor, T. Li, et al., Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts, AAPS PharmSciTech 11 (2010) 1212–1222.

[23] A. Chauhan, P. Chauhan, Powder XRD technique and its applications in science and technology, J. Anal. Bioanal. Tech. 5 (2014) 212.

[24] L. Alexander, H.P. Klug, Determination of crystallite size with the X-Ray spectro-meter, J. Appl. Phys. 21 (1950) 137.

[25] J.I. Langford, A.J.C. Wilson, Scherrer after sixty years: a survey and some new results in the determination of crystallite size, J. Appl. Cryst. 11 (1978) 102–113.

[26] N. Blagden, M. de Matas, P.T. Gavan, et al., Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates, Adv. Drug Deliv. Rev. 59 (2007) 617–630.

[27] M. Inoue, I. Hirasawa, The relationship between crystal morphology and XRD peak intensity on CaSO4·2H2O, J. Cryst. Growth 380 (2013) 169–175.

[28] K. Raza, P. Kumar, S. Ratan, et al., Polymorphism: the phenomenon affecting the performance of drugs, SOJ Pharm. Pharm. Sci. 1 (2014) 1–10.

[29] P. Khadka, J. Ro, H. Kim, et al., Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability, Asian J. Pharm. Sci. 9 (2014) 304–316.

[30] G. Chawla, P. Gupta, R. Thilagavathi, et al., Characterization of solid-state forms of celecoxib, Eur. J. Pharm. Sci. 20 (2003) 305–317.

[31] V.D. Nikolic, D.P. Illic, L.B. Nikolic, et al., The synthesis and characterization of iron (II) gluconate, Adv. Technol. 3 (2014) 16–24.

[32] L. Ji, W. Yin, M. Fu-Jia, Confirmation of the chemical structure of magnesium gluconate, Pharm. Care Res. 4 (2004) 272–273.

[33] M. Hesse, H. Meier, B. Zeeh, Spectroscopic Methods in Organic Chemistry, Georg Thieme Verlag Stuttgart, New York, 1997.

[34] R. Alves, T.V.S. Reis, L.C.C. Silva, et al., Thermal behavior and decomposition kinetics of rifampicin polymorphs under isothermal and non-isothermal condi-tions, Braz. J. Pharm. Sci. 46 (2010) 343–351.

[35] F.J.W.J. Labuschagne, Metal Catalysed Intumescence of Polyhydroxyl Compounds, University of Pretoria, 2003.

Cite this work

Researchers should cite this work as follows:

  • Trivedi, M.K., Journal of Pharmaceutical Analysis (2017),

  • Mahendra Kumar Trivedi; Neena Dixit; Parthasarathi Panda; Kalyan Kumar Sethi; Snehasis Jana (2019), "In-depth investigation on physicochemical and thermal properties of magnesium (II) gluconate using spectroscopic and thermoanalytical techniques,"

    BibTex | EndNote